Claudin and pancreatic cancer

Due to the lack of timely and accurate screening modalities and treatments, most pancreatic cancer (PCa) patients undergo fatal PCa progression within a short period since diagnosis. The claudin(CLDN) family is expressed specifically as tight junction structure in a variety of tumors, including PCa,...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Chen Wang, Na Wu, Beibei Pei, Xiaoyan Ma, Wenhui Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Subjects:	pancreatic cancer (PCA) claudin (CLDN) diagnosis targeted therapy claudin-18.2 claudin-4
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1136227/full

Similar Items

Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer
by: Qian Xu, et al.
Published: (2024-03-01)

Case Report: A case of zolbetuximab-based chemotherapy for Claudin 18.2-positive gastric phenotype adenocarcinoma arising in Meckel’s diverticulum
by: Kohei Nagata, et al.
Published: (2025-11-01)

Claudin18.2 as a Promising Therapeutic Target in Gastric Cancer
by: Agata Poniewierska-Baran, et al.
Published: (2025-08-01)

Future Landscape of Anti-Claudin 18.2 Antibodies in Gastric Adenocarcinoma
by: Wendy M. Covert, et al.
Published: (2025-03-01)

Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2024-02-01)

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
by: Weixiang Zhong, et al.
Published: (2022-06-01)

Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence
by: Su Ir Lyu, et al.
Published: (2024-09-01)

Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2
by: Wu Y, et al.
Published: (2025-03-01)

CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors
by: Gang Xu, et al.
Published: (2024-09-01)

Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution?
by: K. Shimozaki, et al.
Published: (2025-12-01)

Tight Junctions and Cancer: Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies
by: Jędrzej Borowczak, et al.
Published: (2024-09-01)

Tight junctional protein family, Claudins in cancer and cancer metastasis
by: Wenxiao Ji, et al.
Published: (2025-07-01)

Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly
by: Jinlu Liu, et al.
Published: (2023-08-01)

Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report
by: Guocheng Zhong, et al.
Published: (2024-02-01)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
by: Shiyu Liu, et al.
Published: (2023-09-01)

Claudin-18 expression under hyperoxia in neonatal lungs of bronchopulmonary dysplasia model rats
by: Jingye Zuo, et al.
Published: (2022-10-01)

Clinicopathological significance and prognostic values of claudin18.2 expression in solid tumors: a systematic review and meta-analysis
by: Gyerim Park, et al.
Published: (2024-11-01)

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
by: Canming Wang, et al.
Published: (2023-08-01)

Expression and clinical significance of Claudin-1 and Claudin-3 in the serum of patients with psoriasis vulgaris
by: Jinzhao MA, et al.
Published: (2023-06-01)

Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases
by: Du F, et al.
Published: (2024-09-01)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
by: Hongtai Shi, et al.
Published: (2023-07-01)

Targeting claudin‐4 enhances chemosensitivity of pancreatic ductal carcinomas
by: Takamitsu Sasaki, et al.
Published: (2019-11-01)

High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric Cancer
by: Zhang T, et al.
Published: (2024-04-01)

Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
by: Bogdan Silviu Ungureanu, et al.
Published: (2021-03-01)

Anticipatory Testimonies: Environmental Disaster in Claudine Jacques's Fictional Prophecies
by: Julia L Frengs
Published: (2015-01-01)

Differential Expression of Claudin-3 and Claudin-1 in Mycosis Fungoides: Implications for Disease Monitoring
by: Akın Aktaş, et al.
Published: (2025-10-01)

Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study
by: S.J. Klempner, et al.
Published: (2025-03-01)

Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials
by: Zhanpeng Liang, et al.
Published: (2023-10-01)

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis
by: Adrian Georg Simon, et al.
Published: (2023-08-01)

The role and mechanism of claudins in cancer
by: De-Wen Wang, et al.
Published: (2022-12-01)

A Claudin-Based Molecular Signature Identifies High-Risk, Chemoresistant Colorectal Cancer Patients
by: Saiprasad Gowrikumar, et al.
Published: (2021-08-01)

Construction of a Human Immune Library from Gallbladder Cancer Patients for the Single-Chain Fragment Variable (<i>scFv</i>) Antibody Selection against Claudin 18.2 via Phage Display
by: Brian Effer, et al.
Published: (2024-03-01)

Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
by: Katherine I. Zhou, et al.
Published: (2024-08-01)

Expression patterns of claudins in cancer
by: Daoyu Tao, et al.
Published: (2023-11-01)

Deciphering the role of claudins in lung cancer
by: Tarek Ziad Arabi, et al.
Published: (2024-09-01)

Expression of Claudin-9 (CLDN9) in Breast Cancer, the Clinical Significance in Connection with Its Subcoat Anchorage Proteins ZO-1 and ZO-3 and Impact on Drug Resistance
by: Xinguo Zhuang, et al.
Published: (2023-11-01)

CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival
by: Siyue Nie, et al.
Published: (2024-12-01)

Claudin18.2： an emerging target for the treatment of gastric cancer
by: WANG Qiangcheng, BAO Jun
Published: (2024-02-01)

Laparoscopic curative resection following perioperative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel and its influence on Claudin18.2 expression in advanced gastric or gastroesophageal junction adenocarcinoma: a two-case report
by: Tohru Takahashi, et al.
Published: (2025-04-01)

Establishment and verification of prediction model of occult peritoneal metastasis in advanced gastric cancer
by: Hengfei Gao, et al.
Published: (2023-10-01)